Literature DB >> 15665278

A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter.

Wanqing Liu1, Federico Innocenti, Michael H Wu, Apurva A Desai, M Eileen Dolan, Edwin H Cook, Mark J Ratain.   

Abstract

The epidermal growth factor receptor (EGFR) plays a prominent role in cell growth and development. Its regulation in humans is complex and incompletely understood. In this study, 12 new polymorphisms were discovered in the 5'-regulatory region of EGFR gene and 2 common single nucleotide polymorphisms (-216G/T and -191C/A) were found in the essential promoter area, one of which is located in a Sp1 recognition site (-216). Transient transfection in human cancer and primary cell lines showed significantly different promoter activity between the two most common haplotypes (-216G-191C and -216T-191C). The replacement of G by T at position -216 increases the promoter activity by 30%. A transient transfection assay in the Sp1-deficient cell line (Schneider cell line 2) showed a strong dependence of EGFR promoter activity on Sp1 and confirmed the effect of the aforementioned polymorphisms. Electrophoretic mobility shift assay also showed a significantly higher binding efficiency of nuclear protein or pure Sp1 protein to the T allele compared with the G allele. We then investigated the allelic imbalance of EGFR transcription in fibroblast cell lines with heterozygous genotype at -216G/T but C/C homozygous genotype at -191C/A. The expression of mRNA carrying T-C haplotype was significantly stronger compared with that of G-C haplotype (P < 0.02). Thus, we successfully showed that a common polymorphism in the EGFR promoter was associated with altered promoter activity and gene expression both in vitro and in vivo. Our findings have implications for cancer etiology and therapy and may also be relevant to the inherited susceptibility of other common diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15665278

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  66 in total

1.  Novel functional single nucleotide polymorphisms in the latent transforming growth factor-beta binding protein-1L promoter: effect on latent transforming growth factor-beta binding protein-1L expression level and possible prognostic significance in ovarian cancer.

Authors:  Tomomi Higashi; Satoru Kyo; Masaki Inoue; Hideji Tanii; Kiyofumi Saijoh
Journal:  J Mol Diagn       Date:  2006-07       Impact factor: 5.568

Review 2.  The role of pharmacogenetics in cancer therapeutics.

Authors:  Wei Peng Yong; Federico Innocenti; Mark J Ratain
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

Review 3.  The pharmacogenetics research network: from SNP discovery to clinical drug response.

Authors:  K M Giacomini; C M Brett; R B Altman; N L Benowitz; M E Dolan; D A Flockhart; J A Johnson; D F Hayes; T Klein; R M Krauss; D L Kroetz; H L McLeod; A T Nguyen; M J Ratain; M V Relling; V Reus; D M Roden; C A Schaefer; A R Shuldiner; T Skaar; K Tantisira; R F Tyndale; L Wang; R M Weinshilboum; S T Weiss; I Zineh
Journal:  Clin Pharmacol Ther       Date:  2007-03       Impact factor: 6.875

4.  Early skin toxicity predicts better outcomes, and early tumor shrinkage predicts better response after cetuximab treatment in advanced colorectal cancer.

Authors:  T Kogawa; A Doi; M Shimokawa; T M Fouad; T Osuga; F Tamura; T Mizushima; T Kimura; S Abe; H Ihara; T Kukitsu; T Sumiyoshi; N Yoshizaki; M Hirayama; T Sasaki; Y Kawarada; S Kitashiro; S Okushiba; H Kondo; Y Tsuji
Journal:  Target Oncol       Date:  2014-05-27       Impact factor: 4.493

5.  Allelic imbalance (AI) identifies novel tissue-specific cis-regulatory variation for human UGT2B15.

Authors:  Chang Sun; Catherine Southard; David B Witonsky; Olufunmilayo I Olopade; Anna Di Rienzo
Journal:  Hum Mutat       Date:  2010-01       Impact factor: 4.878

6.  EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer.

Authors:  A Sebio; J Salazar; D Páez; A Berenguer-Llergo; E Del Río; M Tobeña; M Martín-Richard; I Sullivan; E Targarona; J Balart; M Baiget; A Barnadas
Journal:  Pharmacogenomics J       Date:  2014-07-15       Impact factor: 3.550

7.  Optimization of PCR conditions for amplification of GC-Rich EGFR promoter sequence.

Authors:  Jasmina Obradovic; Vladimir Jurisic; Natasa Tosic; Jasminka Mrdjanovic; Branislav Perin; Sonja Pavlovic; Natasa Djordjevic
Journal:  J Clin Lab Anal       Date:  2013-11       Impact factor: 2.352

8.  Rapid detection of epidermal growth factor receptor mutations with multiplex PCR and primer extension in lung cancer.

Authors:  Ching-Hsiung Lin; Kun-Tu Yeh; Ya-Sian Chang; Nicholas C Hsu; Jan-Gowth Chang
Journal:  J Biomed Sci       Date:  2010-05-12       Impact factor: 8.410

Review 9.  Emerging ethnic differences in lung cancer therapy.

Authors:  I Sekine; N Yamamoto; K Nishio; N Saijo
Journal:  Br J Cancer       Date:  2008-11-04       Impact factor: 7.640

10.  Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors.

Authors:  Ann Marie Egloff; Jennifer Rubin Grandis
Journal:  J Oncol       Date:  2009-07-14       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.